Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has made a -0.42% comeback from a 12-month low price of $25.97. It was seen -40.9% lower, changing the price to $25.86, when the closing bell rang on 11/07/2017. At recent session, the prices were hovering between $21.41 and $39.18. This company shares are 137.59% off its target price of $61.44 and the current market capitalization stands at $722.01M. The recent change has given its price a -34.17% deficit over SMA 50 and -57.59% deficit over its 52-week high. The stock witnessed -31.98% declines, -9.29% declines and -13.22% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found FPRX’s volatility during a week at 21.03% and during a month it has been found around 8.42%.Five Prime Therapeutics, Inc. (FPRX) Top Holders
Institutional investors currently hold around $1.07 billion or 86.4% in FPRX stock. Look at its top three institutional owners. Fmr Llc owns $188.95 million in Five Prime Therapeutics, Inc., which represents roughly 26.17% of the company’s market cap and approximately 17.68% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 2,923,140 shares of the stock are valued at $127.92 million. The third largest holder is Adage Capital Partners Gp, L.L.C., which currently holds $109.14 million worth of this stock and that ownership represents nearly 15.12% of its market capitalization.
At the end of 06/30/2017 reporting period, 47 institutional holders increased their position in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by some 1,909,543 shares, 83 decreased positions by 1,946,525 and 28 held positions by 20,580,721. That puts total institutional holdings at 24,436,789 shares, according to SEC filings. The stock grabbed 8 new institutional investments totaling 369,795 shares while 37 institutional investors sold out their entire positions totaling 1,090,860 shares.Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Insider Trades
Multiple company employees have indulged in significant insider trading. Five Prime Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Ringo William R has sold 600 shares of Five Prime Therapeutics, Inc. (FPRX) in trading session dated Nov. 01, 2017. These shares are worth $27,198 and were traded at $45.33 each. The SEC filing shows that Ringo William R performed a sale of 1,800 shares. The Director disposed these shares by way of transaction on Oct. 02, 2017. The company’s shares were given away at $40.26 per share worth to an income of some $72,468 on account of Ringo William R.
Director, Ringo William R, sold 2,000 common shares of Five Prime Therapeutics, Inc. (FPRX) in the open market. In a transaction dated Sep. 28, 2017, the shares were put up for sale at an average price of $38, raking in a sum of $76,000.
In the transaction dated Mar. 01, 2017, the great number of shares disposed came courtesy the Director; Ringo William R disposed a total of 500 shares at an average price of $46.73, amounting to approximately $23,365.Five Prime Therapeutics, Inc. (FPRX) Analyst Guide
Several analysts have released their opinion on Five Prime Therapeutics, Inc. (NASDAQ:FPRX), with 5 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.17 average brokerage recommendation.